IRADIMED Reports Q2 Adj. EPS $0.16 vs $0.12 Est., Sales $7.6M vs $7.1M Est.; Raises FY15 Sales, Adj. EPS Outlook, Sees Q3 Sales $7.7M-$7.8M vs $7.4M Est., Adj. EPS $0.16-$0.17 vs $0.13 Est.
Paul Quintaro